Resumption of Illumina Royalty Payment Announced
Financial analysts have noted the upcoming resumption of a royalty payment to Illumina, which is expected to impact future gross margins.
Stocks · News reference
Illumina Selected to Support Precision Medicine in Singapore
Illumina has been selected to contribute to initiatives aimed at integrating precision medicine into everyday healthcare services in Singapore.
Reference Details
Connected Markets
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
- Source
- fiscal.ai
- Observed
- Checked
- Cadence
- Captured once, then retained as an archive reference
- Status
- fresh
Keep reading
Related Headlines
Baird Maintains Hold Rating and Raises Price Target for Illumina
Baird has updated its outlook on Illumina, maintaining a 'Hold' rating while increasing the price target to $236.
Citigroup Maintains Illumina at Sell and Raises Price Target
Citigroup has maintained its "Sell" rating on Illumina, Inc. while increasing the price target from $113 to $210.
Alphabet Posts Worst Week Since 2011, Intel Suffers Record Crash as Warsh Sees 'Cracks': This Week on Wall Street
Alphabet logs its worst week since 2011 and Intel its worst day ever as the AI trade cracks, while health care posts a record month against the market.
Evercore ISI Group Maintains Illumina at Outperform, Lowers Price Target
Evercore ISI Group reaffirmed its 'Outperform' rating on Illumina while adjusting its price target to $275 from $290.
JPMorgan Adjusts Price Target on Illumina to $300 From $320
JPMorgan has revised its price target for Illumina, Inc. (NASDAQ: ILMN), lowering it from $320 to $300.